Xilio Therapeutics, Inc. — Form D
Xilio Therapeutics, Inc. of WALTHAM, MA, a company, filed a Form D exempt-offering notice with the SEC on 2021-01-21. The offering totals $50.2M, of which $50.2M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2021-01-21
- Form: D
- Accession: 0001840233-21-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $50.2M
- Amount sold: $50.2M
- Investors: 16
- Date of first sale: 2021-01-20
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-387002
Issuer
- Name: Xilio Therapeutics, Inc.
- CIK: 0001840233
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2020
- Address: 828 WINTER STREET, WALTHAM, MA, 02451
- Phone: 617-833-1027
Officers, directors & promoters (15)
| Name | Role | Location |
|---|
| Peter Dudek | Director | San Francisco, CA |
| Nancy Hong | Director | Philadelphia, PA |
| Robert Weisskoff | Director | Foster City, CA |
| David Gardner | Director | Cary, NC |
| David Grayzel | Director | Cambridge, MA |
| Michael Ross | Director | South San Francisco, CA |
| Rachel Humphrey | Director | Boston, MA |
| Daniel Lynch | Director | Greenfield, IN |
| Andrew Hack | Director | CAMPBELL, CA |
| Joseph Farmer | Executive Officer | Waltham, MA |
| Rene Russo | Director | Waltham, MA |
| Rene Russo | Executive Officer | Waltham, MA |
| Timothy Clackson | Executive Officer | Waltham, MA |
| Paul Clancy | Director | Waltham, MA |
| Daniel Curran | Director | Waltham, MA |
Other filings by this issuer (1)
More